Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexcom Moves Quickly To Tango With Medtronic In Next-Gen Glucose Testing

This article was originally published in The Gray Sheet

Executive Summary

Eager to hasten adoption of its second-to-market STS continuous glucose monitoring system, DexCom plans to embark any day on a nationwide launch of the just-approved device

You may also be interested in...



Medtronic Looks At Implantable Pancreas In Europe, Mulls U.S. Plans

Despite small glimpses of success with a fully implantable system to monitor glucose in a diabetic's bloodstream and automatically regulate insulin therapy, Medtronic is still mulling whether this approach will ultimately be the focus of its diabetes management program

Medtronic Looks At Implantable Pancreas In Europe, Mulls U.S. Plans

Despite small glimpses of success with a fully implantable system to monitor glucose in a diabetic's bloodstream and automatically regulate insulin therapy, Medtronic is still mulling whether this approach will ultimately be the focus of its diabetes management program

Dexcom Makes Final Preparations On Seven-Day Glucose Monitor Submission

Dexcom plans to submit a PMA supplement for its seven-day STS continuous glucose monitoring system by the end of June

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel